Prominent Birmingham family makes $10 million gift to UAB for Alzheimer’s research
In 2024, Alabama had the sixth-highest rate of Alzheimer’s-related deaths in the country.
The Gorrie family, one of Birmingham’s most prominent names, has committed a $10 million gift to UAB to fuel major advancements in Alzheimer’s Disease research and education. As part of this significant investment, the University of Alabama System Board of Trustees has officially approved the naming of the school’s Alzheimer’s Disease center after Frances Gorrie.
A Legacy of Support
Miller Gorrie, the founder of Brasfield & Gorrie—one of the nation’s largest privately held construction firms—has long been a pillar of support for UAB. This latest contribution is set to catalyze medical innovation, bolster the training of future specialists, and enhance the quality of patient care throughout the region. The center itself, which has served the community since 1991, provides essential research, education, and outreach.
Addressing a Critical Need
This donation comes at a vital time for Alabama, where Alzheimer’s Disease affects nearly 12 percent of the senior population. The state currently faces the sixth-highest rate of Alzheimer’s-related deaths in the United States. Recognizing the urgency, Miller Gorrie stated, “Alzheimer’s disease has touched far too many families, including people I care deeply about. Supporting UAB’s work is my way of honoring those journeys and helping move us closer to better treatments, more hope and, one day, a cure.”
Future Innovations at UAB
Leadership at UAB is already looking ahead to the impact of this funding. David Standaert, chair of the Department of Neurology, noted that the gift arrives at a critical moment where new discoveries are emerging, yet the aging population necessitates more robust resources. According to 205focus.com, this infusion of capital will accelerate the discovery process and provide greater access to care for families across the state.
Specifically, the donation will enable UAB to:
- Expand clinical trial capacity, building on the current five to seven trials typically active at the school.
- Create new endowed faculty positions to attract internationally recognized experts.
- Broaden fellowship opportunities for the next generation of Alzheimer’s specialists.